This page shows the publications co-authored by Clemens Scherzer and Bradley Hyman.
ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696.
Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. Ann Neurol. 2016 09; 80(3):355-67.
Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71.
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7.
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord. 2011 Oct; 26(12):2283-6.
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020; 10(2):505-510.
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology. 2016 Aug 30; 87(9):920-6.
a-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cell Mol Neurobiol. 2016 Apr; 36(3):437-48.
High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol. 2014 Oct; 1(10):822-32.
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar; 71(3):370-84.
Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Nov; 12(6):430-8.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.